PTPRJ

Across TCGA pan-cancer cohorts, PTPRJ mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PTPRJ data layer compared with 23 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher PTPRJ mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PTPRJ expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

LUAD, COAD, and CCRCC are the cancer types where PTPRJ mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.605	0.883	<.001	44	view →
COAD	DFS	Median	II,III,IV	0.902	1.000	.033	30	view →
CCRCC	DFS	Quartile	III,IV	0.140	0.830	.038	6	view →
PDAC	OS	Tertile	III,IV	0.277	0.838	.022	6	view →
HNSC	OS	Median	All	0.903	0.788	.036	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PTPRJ–LUAD (OS)

Open the LUAD breakdown →